{"title":"Dupilumab用于治疗特殊人群的成人特应性皮炎。","authors":"Cataldo Patruno, Luca Potestio, Massimiliano Scalvenzi, Teresa Battista, Flavia Raia, Vincenzo Picone, Gabriella Fabbrocini, Maddalena Napolitano","doi":"10.1080/09546634.2022.2102121","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Special populations (SPs) involve people who require additional consideration in clinical research. Effectiveness of treatment or occurrence of side effects may be different in SPs with respect to not-SPs.</p><p><strong>Objectives: </strong>To retrospectively compare the effectiveness and safety of dupilumab in AD treatment of SPs <i>versus</i> not-SPs.</p><p><strong>Methods: </strong>A 52-weeks retrospective study was performed enrolling patients with a diagnosis of moderate-to-severe AD undergoing treatment with dupilumab at labeled dosage. Patients were divided in Group A (SPs patients) and Group B (not-SPs patients). Disease severity was assessed using Eczema Area Severity Index (EASI), Pruritus-Numerical Rating Scale (P-NRS), and Dermatology Life Quality Index (DLQI) score at baseline and after 4 weeks (W4), W16, W24, and W52.</p><p><strong>Results: </strong>A total of 263 patients were enrolled and divided in Group A (25) and Group B (238). SPs included history of cancer, severe kidney failure, viral hepatitis, neurological diseases, acquired immunodeficiency syndrome, and transplanted patients. A statistically significant reduction of EASI, DLQI, and P-NRS was assessed in both groups at each follow-up visit (<i>p</i> < .0001), without significant differences between the groups. No differences were recorded for safety.</p><p><strong>Conclusions: </strong>There are not significant differences between SPs and not-SPs as regards effectiveness and safety of dupilumab in AD management.</p>","PeriodicalId":15639,"journal":{"name":"Journal of Dermatological Treatment","volume":" ","pages":"3028-3033"},"PeriodicalIF":2.9000,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"16","resultStr":"{\"title\":\"Dupilumab for the treatment of adult atopic dermatitis in special populations.\",\"authors\":\"Cataldo Patruno, Luca Potestio, Massimiliano Scalvenzi, Teresa Battista, Flavia Raia, Vincenzo Picone, Gabriella Fabbrocini, Maddalena Napolitano\",\"doi\":\"10.1080/09546634.2022.2102121\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Special populations (SPs) involve people who require additional consideration in clinical research. Effectiveness of treatment or occurrence of side effects may be different in SPs with respect to not-SPs.</p><p><strong>Objectives: </strong>To retrospectively compare the effectiveness and safety of dupilumab in AD treatment of SPs <i>versus</i> not-SPs.</p><p><strong>Methods: </strong>A 52-weeks retrospective study was performed enrolling patients with a diagnosis of moderate-to-severe AD undergoing treatment with dupilumab at labeled dosage. Patients were divided in Group A (SPs patients) and Group B (not-SPs patients). Disease severity was assessed using Eczema Area Severity Index (EASI), Pruritus-Numerical Rating Scale (P-NRS), and Dermatology Life Quality Index (DLQI) score at baseline and after 4 weeks (W4), W16, W24, and W52.</p><p><strong>Results: </strong>A total of 263 patients were enrolled and divided in Group A (25) and Group B (238). SPs included history of cancer, severe kidney failure, viral hepatitis, neurological diseases, acquired immunodeficiency syndrome, and transplanted patients. A statistically significant reduction of EASI, DLQI, and P-NRS was assessed in both groups at each follow-up visit (<i>p</i> < .0001), without significant differences between the groups. No differences were recorded for safety.</p><p><strong>Conclusions: </strong>There are not significant differences between SPs and not-SPs as regards effectiveness and safety of dupilumab in AD management.</p>\",\"PeriodicalId\":15639,\"journal\":{\"name\":\"Journal of Dermatological Treatment\",\"volume\":\" \",\"pages\":\"3028-3033\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2022-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"16\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Dermatological Treatment\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/09546634.2022.2102121\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2022/7/19 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Dermatological Treatment","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/09546634.2022.2102121","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/7/19 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"DERMATOLOGY","Score":null,"Total":0}
Dupilumab for the treatment of adult atopic dermatitis in special populations.
Background: Special populations (SPs) involve people who require additional consideration in clinical research. Effectiveness of treatment or occurrence of side effects may be different in SPs with respect to not-SPs.
Objectives: To retrospectively compare the effectiveness and safety of dupilumab in AD treatment of SPs versus not-SPs.
Methods: A 52-weeks retrospective study was performed enrolling patients with a diagnosis of moderate-to-severe AD undergoing treatment with dupilumab at labeled dosage. Patients were divided in Group A (SPs patients) and Group B (not-SPs patients). Disease severity was assessed using Eczema Area Severity Index (EASI), Pruritus-Numerical Rating Scale (P-NRS), and Dermatology Life Quality Index (DLQI) score at baseline and after 4 weeks (W4), W16, W24, and W52.
Results: A total of 263 patients were enrolled and divided in Group A (25) and Group B (238). SPs included history of cancer, severe kidney failure, viral hepatitis, neurological diseases, acquired immunodeficiency syndrome, and transplanted patients. A statistically significant reduction of EASI, DLQI, and P-NRS was assessed in both groups at each follow-up visit (p < .0001), without significant differences between the groups. No differences were recorded for safety.
Conclusions: There are not significant differences between SPs and not-SPs as regards effectiveness and safety of dupilumab in AD management.
期刊介绍：
The Journal of Dermatological Treatment covers all aspects of the treatment of skin disease, including the use of topical and systematically administered drugs and other forms of therapy. The Journal of Dermatological Treatment is positioned to give dermatologists cutting edge information on new treatments in all areas of dermatology. It also publishes valuable clinical reviews and theoretical papers on dermatological treatments.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
